On Nov 08, major Wall Street analysts update their ratings for $McKesson (MCK.US)$, with price targets ranging from $612 to $688.
Morgan Stanley analyst Erin Wright maintains with a buy rating, and maintains the target price at $612.
BofA Securities analyst Allen Lutz maintains with a buy rating, and adjusts the target price from $635 to $680.
Barclays analyst Stephanie Davis maintains with a buy rating, and maintains the target price at $668.
Evercore analyst Elizabeth Anderson CFA maintains with a buy rating, and adjusts the target price from $630 to $680.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and adjusts the target price from $652 to $651.
Furthermore, according to the comprehensive report, the opinions of $McKesson (MCK.US)$'s main analysts recently are as follows:
The company's shares saw a 5% increase following a strong performance that addressed concerns regarding long-term target risks.
The firm highlighted that McKesson displayed robust performance across all segments with a particularly strong second-quarter showing in US Pharma. It was also noted that the guidance's midpoint suggests an encouraging acceleration in segment EBIT for fiscal year 25.
McKesson has addressed several issues and eliminated a number of significant uncertainties. The company, along with its peers, has consistently reported positive updates. Furthermore, large-cap healthcare stocks are currently rather undervalued and not widely held. There appears to be no compelling reason why the company would not revert to its recently higher valuation multiples.
Here are the latest investment ratings and price targets for $McKesson (MCK.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月8日，多家华尔街大行更新了$麦克森 (MCK.US)$的评级，目标价介于612美元至688美元。
摩根士丹利分析师Erin Wright维持买入评级，维持目标价612美元。
美银证券分析师Allen Lutz维持买入评级，并将目标价从635美元上调至680美元。
巴克莱银行分析师Stephanie Davis维持买入评级，维持目标价668美元。
Evercore分析师Elizabeth Anderson CFA维持买入评级，并将目标价从630美元上调至680美元。
TD Cowen分析师Charles Rhyee维持买入评级，并将目标价从652美元下调至651美元。
此外，综合报道，$麦克森 (MCK.US)$近期主要分析师观点如下：
公司股票在表现强劲的情况下出现了5%的增长，解决了关于长期目标风险的担忧。
公司强调麦克森在所有板块都表现出色，尤其是美国制药业务在第二季度有着强劲的表现。还指出，指导的中点表明在2025财年，板块EBIt存在令人鼓舞的加速。
麦克森已经解决了几个问题，消除了一些重大的不确定性。与同行一起，该公司一直发布积极的更新。此外，大市值医疗保健股目前相当被低估且不广泛持有。看起来没有令人信服的理由公司为何不会恢复至最近较高的估值倍数。
以下为今日7位分析师对$麦克森 (MCK.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
